Log in to save to my catalogue

Identifying treatment options for BRAF.sup.V600 wild-type metastatic melanoma: A SU2C/MRA genomics-e...

Identifying treatment options for BRAF.sup.V600 wild-type metastatic melanoma: A SU2C/MRA genomics-e...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A657706393

Publication information

Publisher

Public Library of Science

More information

Scope and Contents

Contents

Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAF.sup.V600 mutations, targeted agents have been ineffective for BRAF.sup.V600 wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess w...

Alternative Titles

Full title

Identifying treatment options for BRAF.sup.V600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracacademiconefile_A657706393

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A657706393

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0248097

How to access this item